Pilot study for treating dry age-related macular degeneration (AMD) with high-dose omega-3 fatty acids

Age-related macular degeneration (AMD) is the primary cause of blindness in individuals older than 50 years of age. Studies were carried in patients with dry AMD using high-dose omega-3 fatty acids providing 3.4 g of eicosapentaenoic acid (EPA) and 1.6 g of docosahexaenoic acid (DHA) on a daily basis for 6 months. In patients with dry AMD, significant improvement in vision acuity occurred in 100% of patients was observed within four and half months after omega-3 supplementation.